首页> 外文OA文献 >Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma
【2h】

Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma

机译:单细胞分析揭示了肿瘤内的异质性,并将MLXIP鉴定为肝细胞癌细胞轨迹中的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Hepatocellular carcinoma (HCC) is a globally prevailing cancer with a low 5-year survival rate. Little is known about its intricate gene expression profile. Single-cell RNA sequencing is an indispensable tool to explore the genetic characteristics of HCC at a more detailed level. In this study, we profiled the gene expression of single cells from human HCC tumor and para-tumor tissues using the Smart-seq 2 sequencing method. Based on differentially expressed genes, we identified heterogeneous subclones in HCC tissues, including five HCC and two hepatocyte subclones. We then carried out hub-gene co-network and functional annotations analysis followed pseudo-time analysis with regulated transcriptional factor co-networks to determine HCC cellular trajectory. We found that MLX interacting protein like (MLXIPL) was commonly upregulated in the single cells and tissues and associated with a poor survival rate in HCC. Mechanistically, MLXIPL activation is crucial for promoting cell proliferation and inhibits cell apoptosis by accelerating cell glycolysis. Taken together, our work identifies the heterogeneity of HCC subclones, and suggests MLXIPL might be a promising therapeutic target for HCC.
机译:摘要肝细胞癌(HCC)是与低5年生存率一个全球通行的癌症。知之甚少其复杂的基因表达模式。单细胞RNA测序是探索在一个更详细的级别HCC的遗传特性的不可或缺的工具。在这项研究中,我们从异形使用Smart-SEQ 2测序方法人HCC肿瘤和对肿瘤组织的单细胞的基因表达。基于差异表达的基因,我们确定了肝癌组织异质的亚克隆,包括五个HCC和两个肝细胞的亚克隆。然后我们进行了毂基因共网络和功能注释分析及随后的伪时间分析调节的转录因子共网络确定HCC细胞轨迹。我们发现像(MLXIPL),其MLX相互作用蛋白在单细胞和组织中普遍上调,与肝癌的不良存活率有关。在机制上,MLXIPL激活是通过加速细胞糖酵解促进细胞增殖和抑制细胞凋亡的关键。总之,肝癌亚克隆我们的工作标识的异质性,并提出MLXIPL可能是肝癌有希望的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号